VSY Biotechnology, leading ophthalmic and orthopedic medical device and biotechnology company, announces the appointment of Nagihan ŞENGÜL KARPUZ to the company’s Board of Directors.

Nagihan Şengül Karpuz has been appointed Board Member of VSY Biotechnology. She began her carrier at E&Y and has spent most of her career at Yıldız Holding, working in various areas related to tax compliance,

VSY Biotechnology announces the launch of the Enova® C Haptic Model IOL. Enova® is the first and only 100% Glistening-Free, Dry-Packed hydrophobic acrylic IOL. Moreover, no warming or special conditioning is required before surgery!

VSY Biotechnology Launches Enova® 100% Glistening-Free Hydrophobic Acrylic IOL in C Haptic Model. The unique composition of Enova® material allows uniform hydration of specific sites to have controlled water uptake and resistance to glistening formation.

The 2021 Medical Design Excellence Awards Finalists have been announced! VSY Biotechnology is excited to share that VSY Biotechnology’s Trifocal IOL with Sinusoidal Vision Technology: Acriva Trinova is listed among the finalists of the Medical Design Excellence Awards competition. 

Leinfelden – Echterdingen, Germany April 21, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology,

Germany, March 23, 2021 – VSY Biotechnology, leading ophthalmic and orthopedic medical device and biotechnology company, announces the appointment of seasoned executive leader Can Ongen to the company’s Board of Directors. In this role, Can Ongen will also lead VSY Biotechnology’s sales and marketing activities with a view to further strengthening the company’s position worldwide.

Leinfelden – Echterdingen, Germany March 19, 2021, ­ VSY Biotechnology GmbH, an innovation-driven company with its progressive R&D activities in ophthalmology, visco supplementation in orthopedy and medical esthetics, announced today an agreement with WAKAMOTO PHARMACEUTICAL CO., LTD. (hereinafter refer to “WAKAMOTO PHARMACEUTICAL“) to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with WAKAMOTO PHARMACEUTICAL to develop and launch intraocular lenses (IOLs) in Japan.

VSY Biotechnology GmbH, an innovation-driven company with progressive R&D activities in ophthalmology, has announced the winners of the 2020 Ophthalmology Star Awards. This year’s “Ophthalmology Star Award” is dedicated to Dr. Li Wenliang, an ophthalmologist who was the first to raise the alarm about COVID-19.

Ophthalmologists applied for the contest with their articles until September 18,

Hydrophobic Acrylic IOL that does not Require Pre-hydration and Storage in Saline Solution!

VSY Biotechnology announces Enova, the first 100% glistening-free hydrophobic acrylic IOL that requires neither pre-hydration nor storage in saline. Enova is packaged dry and has excellent optical and mechanical properties.

Leinfelden-Echterdingen, Germany July 22, 2020 ­- VSY Biotechnology GmbH,

VSY Biotechnology announced that it is moving its headquarters from the Netherlands to Germany. VSY Biotechnology GmbH will be the company’s new headquarters.

VSY Biotechnology commenced operations in the late 90s. Since then, the company has achieved several milestones on the way to becoming a global player in the innovation-driven medical device sector.

Applications for this year’s Ophthalmology Star Awards (OSA), organized annually by VSY Biotechnology, will continue until July 15, 2020.

As part of the Ophthalmology Star Awards (OSA), articles by ophthalmologists published in English since January 2019 are being evaluated by an international jury. Ophthalmologists can apply for the contest until July 15, 2020,